Received tentative approval from the FDA for YUTREPIAâ„¢ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung ...
The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...
November is Pulmonary Hypertension Awareness Month, and George Washington University Hospital’s Doctor Mardi Gomberg-Maitland ...
Authors of a recent review shared expert insights and tips for conducting cardiac catheterization procedures to diagnose ...
Westlake Village-based MannKind saw rising revenue and gave a positive update to its orphan lung pipeline when it announced its earnings for the third quarter of 2024. MannKind, a biotechnology ...
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated ...
With a focus on innovation, patient-centered care, and collaboration, Pulnovo Medical, a rising star in the realm of ...
particularly pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Based in San Diego, California, the company utilizes cutting-edge ...
Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...
In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.
Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback